iiinova — where your digital self keeps evolving

gillessa.bsky.social

@gillessa.bsky.social

gillessa.bsky.social @gillessa.bsky.social · 01/05/2026

Online in JCO, impact of TP53mut in DLBCL, a group of patients deserving better therapy. Provocative findings regarding how BTKi might improve their outcome. Congrats to Munna Uppal and Coll ascopubs.org/doi/10.1200/...

ascopubs.org

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma

PURPOSEMutations in TP53, detected in over 20% of diffuse large B-cell lymphomas (DLBCLs), are associated with poor prognosis. However, clinical outcomes among patients with TP53-mutant disease vary, ...

000

Reposted by @gillessa.bsky.social

Memorial Sloan Kettering Continuing Medical Education @mskcme.bsky.social · 06/03/2026

On behalf of Course Director Dr. @gillessa.bsky.social, we invite you to join us April 10–11 for the 10th Anniversary MSK Symposium on #Lymphoma, bringing together distinguished experts from @mskcancercenter.bsky.social and leading institutions around the world. Learn more: bit.ly/lymphoma2026

001

gillessa.bsky.social @gillessa.bsky.social · 24/07/2025

Happy to share this paper written with my so talented colleagues Jenn Lue and Sean Healton

000

gillessa.bsky.social @gillessa.bsky.social · 27/04/2025

Thank you Coraline, it was a privilege to have you among the speakers!

010

Reposted by @gillessa.bsky.social

Memorial Sloan Kettering Continuing Medical Education @mskcme.bsky.social · 24/04/2025

Excited to kick off the 9th MSK Symposium on #Lymphoma tomorrow with a plenary lecture from Dr. Christopher Flowers. Honored to welcome a distinguished faculty and look forward to a compelling program. Details: bit.ly/Lymphoma2025 #MSKlymphomaCME @mskcancercenter.bsky.social @gillessa.bsky.social

011